选择性CDK9抑制剂的设计,合成和活性评估含有英达片段的选择性CDK9抑制剂
Xizhe Sun1, Houlin Peng2, Xiayu Li1
1Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China.
Bioorganic chemistry
|October 14, 2025
概括
一种新的化合物B11显示出作为选择性CDK9抑制剂用于结直肠癌治疗的前景. 它有效地减少了癌细胞的生长,并诱导了细胞亡,这需要进一步的研究.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 循环素依赖性激酶9 (CDK9) 抑制是结直肠癌的潜在治疗策略.
- 开发选择性CDK9抑制剂对于有效的癌症治疗至关重要.
研究的目的:
- 设计和合成基于AZD5438结构的新型CDK9抑制剂.
- 评估合成化合物对结直肠癌细胞系的抗增殖活性和选择性.
- 为了阐明最强效化合物的作用机制.
主要方法:
- 合成28种基于AZD5438结构的新型化合物.
- 针对HCT116,RKO和HT-29结肠直肠癌细胞系的体外抗增殖试验.
- CDK9抑制测定,分子动力学模拟,MM/GBSA计算和亡途径分析.
主要成果:
- 化合物B11对结直肠癌细胞系的抗增殖活性与AZD5438相当.
- B11对CDK9抑制具有优越的选择性,IC50为7.13nM.
- 分子模拟揭示了B11与CDK9.9的选择性结合模式.
- 在HCT116细胞中,B11通过高ROS,抑制的抗亡蛋白和激活的caspase-3诱导了亡.
结论:
- 化合物B11是一种强效和选择性的CDK9抑制剂,具有结直肠癌治疗的潜力.
- B11的机制涉及通过ROS升高和caspase-3激活诱导亡.
- 进一步的临床前开发B11是必要的结直肠癌治疗.
相关概念视频
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis
6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K


